OOIR: Observatory of International Research

Papers

(The median citation count of Drug Resistance Updates is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance	304
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment	188
Anticancer drug resistance: An update and perspective	169
Antimicrobial peptides for combating drug-resistant bacterial infections	163
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	163
The role of alternative splicing in cancer: From oncogenesis to drug resistance	149
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	128
Hypoxia as a driver of resistance to immunotherapy	119
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification	118
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies	117
Novel nanomedicines to overcome cancer multidrug resistance	115
Therapeutic strategies to overcome taxane resistance in cancer	115
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy	110
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	83
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	81
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function	76
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	74
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	74
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs	73
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	69
Long non-coding RNA mediated drug resistance in breast cancer	63
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance	62
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	61
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	60
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	58

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	56
Impact of cancer metabolism on therapy resistance – Clinical implications	55
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer	53
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	52
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	52
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci	51
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	50
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells	50
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	50
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms	49
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology	49
COVID-19 update: The race to therapeutic development	45
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents	44
Cross-resistance and drug sequence in prostate cancer	44
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma	40
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	39
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance	37
Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat	37
KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner	35
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability	35
Molecular Modeling Strategies of Cancer Multidrug Resistance	35
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	35
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	35
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	34
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications	33
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment	33
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer	33
Paclitaxel resistance related to nuclear envelope structural sturdiness	32
Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance	29
Revolutionizing non-conventional wound healing using honey by simultaneously targeting multiple molecular mechanisms	29
Precision medicine: Ray of hope in overcoming cancer multidrug resistance	28
Antibiotic failure: Beyond antimicrobial resistance	28
Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?	28
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	27
Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance	26
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance	26
Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens?	26
Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer	25
Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression	25
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity	25
The role of endolysosomal trafficking in anticancer drug resistance	25
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome	23
Targeted nanomedicine modalities for prostate cancer treatment	23
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia	22
Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis	22
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment	21
The promising role of tumor-associated macrophages in the treatment of cancer	21
The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity	21
Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells	21
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins	19

Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells	19
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae	19
Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia	18
Modulating undruggable targets to overcome cancer therapy resistance	18
Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer	18
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer	18
Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond	18
A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24- enriched breast cancer stem-like cells	17
Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae	17
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica	15
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA	15
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy	15
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance	15
CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis	15
Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC	15
CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma	14
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs	13
Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells	13
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer	13
Carbapenemase-loaded outer membrane vesicles protect Pseudomonas aeruginosa by degrading imipenem and promoting mutation of antimicrobial resistance gene	12
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer	12
Aeromonas spp. from hospital sewage act as a reservoir of genes resistant to last-line antibiotics	11
Hallmarks of anticancer and antimicrobial activities of corroles	11
FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis	11
Acquired non-thermal plasma resistance mediates a shift towards aerobic glycolysis and ferroptotic cell death in melanoma	11
Evolution of RND efflux pumps in the development of a successful pathogen	11
CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress	10
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma	10
Mapping cryptic binding sites of drug targets to overcome drug resistance	10
GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells	10
Targeting Myc-driven stress addiction in colorectal cancer	10
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance	10
MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma	10
Genetic alterations shaping tumor response to anti-EGFR therapies	9
CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis	9
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2	9
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer	9
Combating bacterial infections with host defense peptides: Shifting focus from bacteria to host immunity	9
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma	9
Cage-modified hypocrellin against multidrug-resistant Candida spp. with unprecedented activity in light-triggered combinational photodynamic therapy	8
Cisplatin-activated ERβ/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis	8
Identification of TMexCD-TOprJ-producing carbapenem-resistant Gram-negative bacteria from hospital sewage	8
Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies	8
CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer	8